The complaint centers on allegations that Erasca provided false and misleading statements about the development of ERAS-0015. According to the filing, the company’s preclinical data relied on an improper comparison to Revolution Medicines, Inc., creating significant patent infringement risks that were not disclosed to shareholders. Plaintiffs argue these optimistic claims lacked a factual basis, artificially inflating the company's valuation during the specified class period.
In section Releases
Erasca Shareholders Face August 10 Deadline in Securities Class Action
Investors who purchased Erasca, Inc. stock between January 14, 2025, and April 26, 2026, are running out of time to seek lead plaintiff status in a pending securities fraud lawsuit. The litigation, filed by Schall, Brown & Schwartz LLP, alleges the company misled the market regarding its ERAS-0015 drug candidate.
Investors who suffered financial losses due to these disclosures may contact attorneys Brian Schall or David Schwartz at the Los Angeles-based firm Schall, Brown & Schwartz LLP. While the class has not yet been certified, those who held shares during the relevant timeframe have until August 10, 2026, to file for lead plaintiff appointment. Participation in the lawsuit does not require individuals to take on the lead plaintiff role, though those who choose to take no action will remain absent class members without independent legal representation.
Comments (0)
No comments yet. Be the first!